Enanta Pharmaceuticals reported $16.96M in Sales Revenues for its fiscal quarter ending in December of 2024.





Sales Change Date
AbbVie USD 17.4B 410M Sep/2026
Amgen USD 10.4B 300M Sep/2026
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 450.82M 375.59M Sep/2026
AstraZeneca USD 16.21B 830M Sep/2026
BioCryst Pharmaceuticals USD 218.25M 188.3M Jun/2026
Biogen USD 2.8B 60M Sep/2026
Bristol-Myers Squibb USD 13.07B 100M Sep/2026
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
Gilead Sciences USD 8.3B 500M Sep/2026
GlaxoSmithKline GBP 8.89B 480M Sep/2026
Halozyme Therapeutics USD 492.97M 11.97M Sep/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Incyte USD 1.56B 110M Sep/2026
Insmed USD 524.42M 98.93M Sep/2026
Ionis Pharmaceuticals USD 243M 25M Sep/2026
J&J USD 25.4B 89M Sep/2026
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
Ligand Pharmaceuticals USD 78.75M 4.95M Sep/2026
Merck USD 18.1B 1.5B Sep/2026
Neurocrine Biosciences USD 1.12B 161M Sep/2026
Novartis USD 14.52B 112M Sep/2026
Novavax USD 147.14M 76.69M Dec/2025
Pfizer USD 16.6B 1.57B Sep/2026
PTC Therapeutics USD 357.8M 3.2M Sep/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Sarepta Therapeutics USD 381.4M 19.9M Sep/2026
Vertex Pharmaceuticals USD 3.44B 110M Sep/2026